Centre for Human & Applied Physiological Sciences, King's College London School of Medical Education, London, UK
Department of Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.
BMJ Support Palliat Care. 2020 Mar;10(1):45-54. doi: 10.1136/bmjspcare-2018-001610. Epub 2019 Jun 26.
Malignant pleural effusion (MPE) results in breathlessness and impairment of health-related quality of life (HRQOL). This study reviews the existing literature on HRQOL following invasive interventions in MPE.
Five electronic databases were systematically searched and assessed three times during the review process and last completed on 15 June 2018. We included all studies evaluating HRQOL outcomes for the following interventions: therapeutic thoracocentesis, talc slurry (TS) pleurodesis, indwelling pleural catheter (IPC) insertion and thoracoscopic talc poudrage (TTP) pleurodesis. Meta-analysis was not performed due to substantial heterogeneity in the published data.
17 studies were included in the review reporting HRQOL outcomes in 2515 patients. TTP, TS and IPC were associated with modest but inconsistent improvements in HRQOL up to 12 weeks. No intervention was significantly different from another in HRQOL outcomes at any time point. The attrition to follow-up was 48.3% (664/1374) at 3 months. The overall quality of studies was inadequate.
TTP, TS and IPC seem to improve HRQOL in MPE over 4-12 weeks, but there are insufficient longer term data due to high attrition rates. Evidence on the most effective treatment strategy is limited by the small number of randomised or comparative studies.
CRD42016051003.
恶性胸腔积液(MPE)可导致呼吸困难和健康相关生活质量(HRQOL)受损。本研究回顾了 MPE 患者接受侵袭性干预后的 HRQOL 现有文献。
系统检索了五个电子数据库,并在审查过程中进行了三次评估,最后一次评估于 2018 年 6 月 15 日完成。我们纳入了所有评估以下干预措施 HRQOL 结局的研究:治疗性胸腔穿刺术、滑石粉混悬液(TS)胸膜固定术、留置胸膜导管(IPC)插入术和胸腔镜滑石粉喷洒(TTP)胸膜固定术。由于发表数据存在很大的异质性,因此未进行荟萃分析。
共纳入了 17 项研究,报道了 2515 例患者的 HRQOL 结局。TTP、TS 和 IPC 与 HRQOL 在 4 至 12 周内适度但不一致的改善相关。在任何时间点,任何干预措施在 HRQOL 结局上均无显著差异。3 个月时的随访失访率为 48.3%(664/1374)。总体研究质量欠佳。
TTP、TS 和 IPC 似乎可在 4 至 12 周内改善 MPE 患者的 HRQOL,但由于失访率较高,缺乏更长期的数据。由于随机或对照研究数量较少,因此关于最有效治疗策略的证据有限。
CRD42016051003。